BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.
| Revenue (Most Recent Fiscal Year) | $2.98B |
| Net Income (Most Recent Fiscal Year) | $-719.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.12 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.21 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -28.38% |
| Net Margin (Trailing 12 Months) | -27.37% |
| Return on Equity (Trailing 12 Months) | -3.94% |
| Return on Assets (Trailing 12 Months) | -3.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.18 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | 1.91 |
| Book Value per Share (Most Recent Fiscal Quarter) | $82.94 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.82 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.40 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 240.39M |
| Free Float | 194.24M |
| Market Capitalization | $24.10B |
| Average Volume (Last 20 Days) | 0.82M |
| Beta (Past 60 Months) | 1.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.52% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |